S13:E2 – Oncology Morning Commute: Managing Adverse Events That Occur With PARP Inhibition Therapies—What Your Patients Need to Know

Hematology / Oncology @Point of Care Podcasts

English - December 16, 2022 04:11 - 40.8 MB
Medicine Health & Fitness checkpointinhibitors cmece endometrialcancer immunotherapy Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: S13:E1 – Oncology Morning Commute: Patient Selection for Treatment With PARP Inhibitors in Ovarian Cancer

Next Episode: S13:E3 – Oncology Morning Commute: What’s Next in Using PARP Inhibitors for Patients With Ovarian Cancer?

In this podcast, our faculty continue their discussion about PARP inhibitors and take it down to the clinical level. Who are the best candidates for these therapies and how are adverse events managed for the best outcomes?

Visit http://www.MorningCommutePodcast.com/OvarianCancer2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit